# A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

> **NCT04078295** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eisai Co., Ltd.** · enrollment: 125 (actual)

## Conditions studied

- Solid Neoplasms

## Interventions

- **DRUG:** E7389-LF
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04078295
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-05
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04078295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04078295, "A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04078295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*